文献速递重症综合管理与镇静镇痛心脑血管急症

丙戊酸用于神经外科重症监护病房患者躁动管理

Valproic acid for the management of agitation in neurosurgical intensive care unit patients.
PubMed 文献 · Neurocrit Care · 2026-03-24
一句话结论单中心回顾性研究显示,神经外科ICU躁动患者启动丙戊酸后第3天阿片类、苯二氮䓬类和右美托咪定日均总剂量及RASS阳性评分、身体约束使用均显著减少。

本研究为单中心回顾性描述性研究,纳入2016年4月1日至2023年8月31日期间因躁动接受丙戊酸至少3天的成人神经外科ICU患者共91例。主要终点为丙戊酸启动后辅助镇静药物日均总剂量变化,次要终点包括RASS阳性评分发生率和身体约束解除情况,安全性终点包括血小板减少、高氨血症和肝功能异常。结果显示丙戊酸治疗第3天阿片类(p=0.001)、苯二氮䓬类(p=0.003)和右美托咪定(p<0.001)日均总剂量显著降低,RASS阳性评分患者数(p=0.001)和需身体约束患者数(p=0.001)从第1天至第3天显著减少。作者认为需进一步前瞻性研究确定丙戊酸在神经外科ICU躁动管理中的最佳作用。

要点

  • 单中心回顾性研究纳入91例成人神经外科ICU躁动患者,丙戊酸治疗至少3天。
  • 丙戊酸第3天阿片类(p=0.001)、苯二氮䓬类(p=0.003)和右美托咪定(p<0.001)日均总剂量显著降低。
  • RASS阳性评分患者数(p=0.001)和需身体约束患者数(p=0.001)从第1天至第3天显著减少。
  • 安全性终点包括血小板减少、高氨血症和肝功能异常。
  • 作者认为需进一步前瞻性研究确定丙戊酸在神经外科ICU躁动管理中的最佳作用。

适用人群与场景

  • 成人神经外科ICU患者,因躁动接受丙戊酸治疗至少3天,纳入时间为2016年4月1日至2023年8月31日。

研究设计与关键结果

  • 单中心回顾性描述性研究,共纳入91例成人神经外科ICU躁动患者。
  • 主要终点:丙戊酸启动后第3天辅助镇静药物日均总剂量显著降低,阿片类p=0.001、苯二氮䓬类p=0.003、右美托咪定p<0.001。
  • 次要终点:RASS阳性评分患者数(p=0.001)和需身体约束患者数(p=0.001)从丙戊酸治疗第1天至第3天显著减少。
  • 安全性终点:评估丙戊酸治疗期间血小板减少、高氨血症和肝功能异常的发生情况。

证据类型、等级与局限

  • 证据类型:单中心回顾性描述性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,丙戊酸启动与辅助镇静药物需求、RASS阳性评分及需身体约束患者数显著减少相关。
  • 作者认为,需进一步前瞻性研究确定丙戊酸在神经外科ICU躁动管理中的最佳作用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Neurosurgical patients are at an increased risk of developing agitation and intensive care unit (ICU) delirium due to direct inflammation and oxidative stress associated with neurosurgery. There are limited therapeutic options for the management of agitation and delirium in this population; and neurosurgical patients have been largely underrepresented in previous studies. This study aimed to assess the impact of valproic acid (VPA) on adjunctive agent requirements for the management of agitation in neurosurgical ICU patients.

METHODS: This was a single-center, retrospective, descriptive study evaluating adult neurosurgical patients admitted between 1 April 2016 and 31 August 2023. Patients were included if they were on VPA for at least 3 days for the treatment of agitation. The primary outcome evaluated changes in total daily doses (TDD) of adjunctive sedative agent requirements following VPA initiation. Secondary outcomes included the incidence of positive Richmond Agitation and Sedation Scale (RASS) scores and liberation from physical restraints. Safety outcomes included the occurrence of thrombocytopenia, hyperammonemia, and liver function test (LFT) abnormalities while on VPA.

RESULTS: A total of 91 patients were included in the analysis. Significant reductions in TDD of opioids (p = 0.001), benzodiazepines (p = 0.003), and dexmedetomidine (p < 0.001) were seen on day 3 of VPA therapy. Significant reductions in the number of patients with positive RASS scores (p = 0.001) and the number of patients requiring physical restraints (p = 0.001) were also observed from day 1 to day 3 of VPA therapy.

CONCLUSIONS: Initiation of VPA was associated with a significant decrease in adjunctive sedative agent requirements, positive RASS scores, and number of patients requiring physical restraints. Further prospective studies are needed to determine the optimal role of VPA for the management of agitation in neurosurgical ICU patients.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Thomas L, Livers K, Sieg E, et al. Valproic acid for the management of agitation in neurosurgical intensive care unit patients. Neurocrit Care. 2026. PMID: 41876915. doi:10.1007/s12028-026-02484-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。